References
- 1. Abraham S, Shaju M. Innovations in epilepsy management - an overview. J Pharm Pharm Sci 2013; 16(4):564-76.
- 2. Atlas: Epilepsy Care in the World. Geneva, Switzerland: World Health Organization; 2005. 91p.
- 3. Magiorkinis E, Diamantis A, Sidiropoulou K, Panteliadis C. Highights in the history of epilepsy: the last 200 years. Epilepsy Res Treat 2014; 2014:582039.
- 4. Simonato M, French JA, Galanopoulou AS, O’Brien TJ. Issues for new antiepilepsy drug development. Curr Opin Neurol 2013; 26(2):195-200.
- 5. Laxer KD, Trinka E, Hirsch LJ, et al. The consequences of refractory epilepsy and its treatment. Epilepsy Behav 2014; 37C:59-70.
- 6. Löscher W, Klotz U, Zimprich F, Schmidt D. The clinical impact of pharmacogenetics on the treatment of epilepsy. Epilepsia 2009; 50(1):1-23.
- 7. Thorn CF, Leckband SG, Kelsoe J, et al. PharmGKB summary: carbamazepine pathway. Pharmacogenet Genomics 2011; 21(12):906-10.
- 8. Jankovic SM, Jovanovic D, Milovanovic JR. Pharmacokinetic modeling of carbamazepine based on clinical data from Serbian epileptic patients. Methods Find Exp Clin Pharmacol 2008; 30(9):707-13.
- 9. Kerr BM, Thummel KE, Wurden CJ, et al. Human liver carbamazepine metabolism. Role of CYP3A4 and CYP2C8 in 10,11-epoxide formation. Biochem Pharmacol 1994; 47(11):1969-79.
- 10. Zanger UM, Schwab M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacology & Therapeutics 2013; 138:103-41.
- 11. Lee SJ, Usmani KA, Chanas B, et al. Genetic findings and functional studies of human CYP3A5 single nucleotide polymorphisms in different ethnic groups. Pharmacogenetics 2003; 13:461–472.
- 12. Hesselink DA, van Schaik RHN, van der Heiden IP, et al. Genetic polymorphisms of the CYP3A4, CYP3A5, and MDR-1 genes and pharmacokinetics of the calcineurin inhibitors cyclosporine and tacrolimus. Clin Pharmacol Ther 2003; 74:245-54.
- 13. Jin Y, Wang YH, Miao J, et al. Cytochrome P450 3A5 genotype is associated with verapamil response in healthy subjects. Clin Pharmacol Ther 2007; 82:579–85.
- 14. Josephson F, Allqvist A, Janabi M, et al. CYP3A5 genotype has an impact on the metabolism of the HIV protease inhibitor saquinavir. Clin Pharmacol Ther 2007; 81:708-12.
- 15. Park PW, Seo YH, Ahn JY, et al. Effect of CYP3A5*3 genotype on serum carbamazepine concentrations at steady-state in Korean epileptic patients. J Clin Pharm Ther 2009; 34(5):569-574.
- 16. Meng H, Ren J, Lv Y, et al. Association study of CYP3A5 genetic polymorphism with serum concentrations of carbamazepine in Chinese epilepsy patients. Neurology Asia 2011; 16(1):39-45.
- 17. Seo T, Nakada N, Ueda N, et al. Effect of CYP3A5*3 on carbamazepine pharmacokinetics in Japanese patients with epilepsy. Clin Pharmacol Ther 2006; 79(5):509-10.
- 18. Puranik YG, Birnbaum AK, Marino SE, et al. Association of carbamazepine major metabolism and transport pathway gene polymorphisms and pharmacokinetics in patients with epilepsy. Pharmacogenomics 2013; 14(1):35-45.
- 19. Chen ML. Ethnic or racial differences revisited: impact of dosage regimen and dosage form on pharmacokinetics and pharmacodynamics. Clin Pharmacokinet 2006; 45(10):957-64.
- 20. Yasuda SU, Zhang L, Huang SM. The role of ethnicity in variability in response to drugs: focus on clinical pharmacology studies. Clin Pharmacol Ther 2008; 84(3):417-23.
- 21. Yokoi T. Essentials for starting a pediatric clinical study (1): Pharmacokinetics in children. J. Toxicol. Sci. 2009; 34(II):SP307-SP312.
- 22. van Schaik RH, van der Heiden IP, van den Anker JN, Lindemans J. CYP3A5 variant allele frequencies in Dutch Caucasians. Clin Chem 2002; 48(10):1668-71.
- 23. King BP, Leathart JB, Mutch E, et al. CYP3A5 phenotype-genotype correlations in a British population. Br J Clin Pharmacol 2003; 55(6):625-9.
- 24. Sweetman S, ed. Martindale: The complete drug reference 36. Pharmaceutical Press; 2009.
- 25. Spurr NK, Gough AC, Stevenson K, Wolf CR. The human cytochrome P450 CYP3A locus: assignment to chromosome 7g22-qter. Hum Genet 1989; 81(2):171-4.
- 26. Chen X, Wang HW, Zhou G, et al. Molecular population genetics of human CYP3A locus: signatures of positive selection and implications for evolutionary environmental medicine. Environmental Health Perspectives 2009; 117(10):1541-8.
- 27. Xie HG, Wood AJJ, Kim RB, et al. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5(3):243–272.
- 28. Kuehl P, Zhang J, Lin Y, et al. Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression. Nat Genet 2001; 27:383-391.
- 29. Hiratsuka M, Takekuma Y, Endo N, et al. Allele and genotype frequencies of CYP2B6 and CYP3A5 in the Japanese population. Eur J Clin Pharmacol 2002; 58:417-421.
- 30. Hustert E, Haberl M, Burk O, et al. The genetic determinants of the CYP3A5 polymorphism. Pharmacogenetics 2001; 11:773-779.
- 31. Givens RC, Lin YS, Dowling AL, et al. CYP3A5 genotype predicts renal CYP3A activity and blood pressure in healthy adults. J Appl Physiol (1985) 2003; 95(3):1297-300.
- 32. Bhatnagar V, Garcia EP, O’Connor DT, et al. CYP3A4 and CYP3A5 polymorphisms and blood pressure response to amlodipine among African-American men and women with early hypertensive renal disease. Am J Nephrol 2010; 31(2):95-103.
- 33. Hu YF, He J, Chen GL, et al. CYP3A5*3 and CYP3A4*18 single nucleotide polymorphisms in a Chinese population. Clin Chim Acta 2005; 353:187–192.
- 34. Saeki M, Saito Y, Nakamura T, et al. Single nucleotide polymorphisms and haplotype frequencies of CYP3A5 in a Japanese population. Hum Mutat 2003; 618:1-7.
- 35. Arvanitidis K, Ragia G, Iordanidou M, et al. Genetic polymorphisms of drug-metabolizing enzymes CYP2D6, CYP2C9, CYP2C19 and CYP3A5 in the Greek population. Fundam Clin Pharmacol 2007; 21(4):419-26.
- 36. Hilli J, Rane A, Lundgren S, et al. Genetic polymorphism of cytochrome P450s and P-glycoprotein in the Finnish population. Fundamental & Clinical Pharmacology 2007; 21:379–86.
- 37. Borst L, Wallerek S, Dalhoff K, et al. The impact of CYP3A5*3 on risk and prognosis in childhood acute lymphoblastic leukemia. Eur J Haematol 2011; 86(477–83).
- 38. Sailaja K, Rao DN, Rao DR, Vishnupriya S. Analysis of CYP3A5*3 and CYP3A5*6 gene polymorphisms in Indian chronic myeloid leukemia patients. Asian Pac J Cancer Prev 2010; 11(781-4).
- 39. Shimada N, Iwasaki M, Kasuga Y, et al. Genetic polymorphisms in estrogen metabolism and breast cancer risk in case-control studies in Japanese, Japanese Brazilians and non-Japanese Brazilians. J Hum Genet 2009; 54(209-15).
- 40. Mefford HC. CNVs in Epilepsy. Curr Genet Med Rep 2014; 2:162-167.
- 41. Helbig I, Lowenstein DH. Genetics of the epilepsies: where are we and where are we going? Curr Opin Neurol 2013; 26(2):179-85.
- 42. Kim KA, Park PW, Lee OJ, et al. Effect of CYP3A5*3 genotype on the pharmacokinetics and pharmacodynamics of amlodipine in healthy Korean subjects. Clin Pharmacol Ther 2006; 80:646-56.
- 43. Kim KA, Park PW, Lee OJ, et al. Effect of polymorphic CYP3A5 genotype on the single-dose simvastatin pharmacokinetics in healthy subjects. J Clin Pharmacol 2007; 47:87-93.
- 44. Eap CB, Buclin T, Hustert E, et al. Pharmacokinetics of midazolam in CYP3A4- and CYP3A5-genotyped subjects. Eur J Clin Pharmacol 2004; 60:231-6.
- 45. Fukuda T, Onishi S, Fukuen S, et al. CYP3A5 genotype did not impact on nifedipine disposition in healthy volunteers. Pharmacogenomics J 2004; 4(1):34-9.
- 46. Yamamoto T, Kubota T, Ozeki T, et al. Effects of the CYP3A5 genetic polymorphism on the pharmacokinetics of diltiazem. Clin Chim Acta 2005; 362(1-2):147-54.
- 47. Emich-Widera E, Likus W, Kazek B, et al. CYP3A5*3 and C3435T MDR1 polymorphisms in prognostication of drug-resistant epilepsy in children and adolescents. Biomed Res Int 2013; 2013:526837.
- 48. Semiz S, Dujic T, Ostanek B, et al. Analysis of CYP3A4*1B and CYP3A5*3 polymorphisms in population of Bosnia and Herzegovina. Med Glas (Zenica) 2011; 8:84-9.
- 49. Jakovski K, Kapedanovska Nestorovska A, Labacevski N, Dimovski AJ. Frequency of the most common CYP3A5 polymorphisms in the healthy population of the Republic of Macedonia. Macedonian pharmaceutical bulletin 2012; 58(1,2):25-30.
- 50. Turolo S, Tirelli AS, Ferraresso M, et al. Frequencies and roles of CYP3A5, CYP3A4 and ABCB1 single nucleotide polymorphisms in Italian teenagers after kidney transplantation. Pharmacol Rep 2010; 62:1159–69.
- 51. Adler G, Loniewska B, Parczewski M, et al. Frequency of common CYP3A5 gene variants in healthy Polish newborn infants. Pharmacol Rep 2009; 61:947–51.
- 52. Bosch TM, Doodeman VD, Smits PHM, et al. Pharmacogenetic screening for polymorphisms in drug-metabolizing enzymes and drug transporters in a Dutch population. Mol Diag Ther 2006; 10(3):175-185.
- 53. Seredina TA, Goreva OB, Talaban VO, et al. Association of cytochrome P450 genetic polymorphisms with neoadjuvant chemotherapy efficacy in breast cancer patients. BMC Med. Genet 2012; 13:45.
- 54. Wong M, Balleine RL, Collins M, et al. CYP3A5 genotype and midazolam clearance in Australian patients receiving chemotherapy. Clin Pharmacol Ther 2004; 75(6):529-38.
- 55. Djordjevic N, Jankovic S, Bertilsson L, Aklillu E. CYP3A4 i CYP3A5 genetski polimorfizam kod Srba. Med Cas 2008; 42(1):Suppl 1: 29.
- 56. Stefanovic N, Cvetkovic T, Velickovic-Radovanovic R, et al. Significance of CYP3A5 gene polymorphism in Serbian renal transplant patients. Acta Medica Medianae 2013; 52(1):33-8.
- 57. Balram C, Zhou Q, Cheung YB, Lee EJD. CYP3A5*3 and *6 single nucleotide polymorphisms in three distinct Asian populations. Eur J Clin Pharmacol 2003; 59:123–126.
- 58. Liu CH, Peck K, Huang JD, et al. Screening CYP3A single nucleotide polymorphisms in a Han Chinese population with a genotyping chip. Pharmacogenomics 2005; 6(7):731-47.